Genetic medicines

Gene editing concept
#Biotechnology #Broken String Biosciences #Gene editing #Genetic medicines #Genetics

Base editing to enable single-base genomic changes

Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, has launched BaseMap ABE. Built on the company’s INDUCE-seq technology, BaseMap ABE extends the platform’s capabilities to support adenine base editing (ABE) applications. Base editing is rapidly gaining momentum as a… Read More

#News

Researcher pipetting samples in microplate
#ASGCT #DNA #Genetic medicines

Company shows ‘new therapeutic modality’ at ASGCT 2026 

Serif Biomedicines has announced preclinical data showing the potential of its Modified DNA as a new class of genetic medicines.  Results from non-human primates, announced at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026, suggest Modified DNA could overcome barriers of innate immune… Read More

#News

Hepatitis B
#Clinical trial #Genetic medicines #Viral hepatitis

nChroma Bio set to trial chronic hepatitis B virus treatment 

Genetic medicines company nChroma Bio has received a Certificate for Clinical Trial in Hong Kong to start the Phase I/II trial of its treatment for chronic hepatitis B virus (HBV).  CRMA-1001 is an optimised next-generation epigenetic silencer, designed to durably silence HBV antigen expression by methylating both covalently closed circular… Read More

#News

#Gene synthesis #Genetic medicines #Guide #Synthetic DNA

Guide: Next generation cell-free gene synthesis

Struggling to make sense of the strategies, technology and trade-offs when developing a DNA supply chain? Elegen has created a comprehensive overview of the evolving field of gene synthesis entitled ‘The Next-Gen DNA Buyers Guide: From design to results faster and more reliably with cell-free gene synthesis’. The Guide… Read More

#News

#Gene synthesis #Genetic medicines #Synthetic DNA

Next generation cell-free gene synthesis

Struggling to make sense of the strategies, technology and trade-offs when developing a DNA supply chain? Elegen created a comprehensive overview of the evolving field of gene synthesis. This Guide contains a detailed comparison of 10 industry-leading vendors, including key metrics such as error rate, turnaround time, cost, and maximum… Read More

#Intelligence #Resources

Bladder
#EG 427 #Financing #Genetic medicines #Neurodegenerative disorders

EG 427 raises €27m to finance genetic medicines in neuro-urology

EG 427 has announced the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance – as part of the InnoBio investment strategy.    The proceeds from the financing will be used to fund the Phase Ib/IIa development of EG 427’s lead genetic medicine product,… Read More

#Business & Investment #News

#Bill & Melinda Gates Foundation #Funding #Genetic medicines #Sickle cell disorder (SCD) #Tessera Therapeutics

Investment to develop in vivo genetic treatment for sickle cell disease

Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company’s in vivo programme for sickle cell disease (SCD). The funding includes an initial investment, with potential total investment of up to $50… Read More

#News

Oligonucleotide
#Alpha-1 antitrypsin deficiency #Biopharmaceuticals #Genetic medicines #Korro Bio #Oligonucleotides #RNA

RNA editing oligonucleotide selected for AATD treatment 

Korro Bio, a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of alpha-1 antitrypsin deficiency (AATD).   KRRO-110 is an RNA editing oligonucleotide delivered to liver cells… Read More

#News